-Reuters
F-star’s FS118 Development Program To Include Checkpoint Naïve Cancer Patients
F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients. The new study will…